Shareholders in 2seventy bio, Inc. ( NASDAQ:TSVT ) had a terrible week, as shares crashed 22% to US$3.92 in the ...

Revenue missed analyst estimates by 7.0%. Earnings per share (EPS) exceeded analyst estimates by 21%. Looking ahead, revenue ...

Biopharma giant Gilead Sciences will shut down its office in Seattle's Eastlake neighborhood, the company confirmed to ...

Seventy Bio, Inc. ( (TSVT) ) has released its Q3 earnings. Here is a breakdown of the information 2Seventy Bio, Inc. presented to its ...

News release. Janssen. February 28, 2022. https://bit.ly/35yWwjv U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Inc. (TSVT) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $1 per share a year ago. These figures are adjusted for ...

The company ended the quarter with $192 million in cash and equivalents, enough to fund operations past 2027. 2seventy Bio ...

MacStadium, the industry-leading Mac virtualization and cloud services provider, today announced the launch of Orka Engine, the latest addition to its Orka product line. Orka Engine allows mobile app ...

Senstar Technologies Corporation , a leading international provider of comprehensive physical, video and access control security products and solutions, today announced its financial results for the ...

The latest announcement is out from 2seventy bio ( (TSVT) ). 2seventy bio reported impressive third-quarter results with a 42% increase in ...

Shares of 2seventy bio were trading at $4.73 as of November 07. Over the last 52-week period, shares are up 107.46%. Given that these returns are generally positive, long-term shareholders should be ...